samedan logo
 
 
spacer
home > ict > spring 2009 > centre-controlled trials
PUBLICATIONS
International Clinical Trials

Centre-Controlled Trials

 

Randomisation is the cornerstone of statistical inference and, as such, scientists go to great lengths to preserve its integrity. Randomisation is particularly important in the pharmaceutical industry, as regulatory agencies worldwide insist on definitive clinical trials conducted in a randomised fashion. In fact, most of these definitive trials are conducted with the clinician and patient unaware of the particular treatment being received by the patient (double-blind trials). This is done to eliminate potential bias in the collection and reporting of information about the patient. Additionally, the statisticians responsible for summarising the information from these trials are also kept ‘blinded’ to the randomisation scheme prior to conducting the final analysis so as not to bias the manner in which the data are scrutinised.

Randomisation can come in many forms. The first of these is simple random sampling (SRS). With SRS, each patient is equally likely to get any of the possible treatments. This presents a problem in multi-centre trials as a balance between treatments is maintained overall but not within a given centre. To better accommodate the multi-centre trial, stratified random sampling can be performed where each centre is considered as a stratum. This greatly improves the balance within centres, but is still not completely effective. In practice, most multi-centre trials use a permuted block design, which allows for the balance between treatments to be maintained within each centre over the course of the trial. There are situations where it would be beneficial to favour one treatment arm over another, based on informative covariates or patient outcomes. In these cases, adaptive randomisation may be useful.

OBJECTIVES OF ADAPTIVE RANDOMISATION

Adaptive randomisation seeks to use cumulative patient information, being gathered on an ongoing basis, to determine the allocation of subsequent patients to the treatment arms.

Adaptive randomisation trials can improve the efficiency of clinical trials by enrolling fewer patients into treatments that are less likely to succeed, by improving the quality of results so that more patients are enrolled in successful treatments, and increasing the chances that patients will receive effective treatments.

TYPES OF ADAPTATIONS

Covariate Adaptive Randomisation When covariates are known to be correlated with the response being studied, it is often desirable to balance on these factors using a stratified approach. In certain situations, however, it is impractical (due to financial considerations or insufficient patient population) to use a stratified approach within each study centre. Covariate adaptive randomisation can be an alternative to stratified random sampling. The system works by balancing important prognostic factors across the entire study, while allowing a balance between treatments to be maintained within each study centre. This is done by examining the balance within the centre, as well as the balance across the study with respect to the covariates, and then using prespecified rules to favour the under-represented treatment group on the factor which is the most out of balance. Several methods have been proposed and they are discussed briefly here.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

James Trammel, MS, is Principal Biostatistician at i3 Statprobe, and a member of the Adaptive Design Consulting Group. James assists in protocol design, trial randomisation, statistical analysis plan development, programming plan creation and senior statistical oversight. He is responsible for adaptive randomisation through i3 Statprobe’s Adaptive Design Consulting Group. Prior to joining i3, James spent 10 years as a senior statistician at Red River Statistics, consulting in the pharmaceutical business. James holds a Master’s Degree in Statistics from the University of Southwestern Louisiana and a Bachelor’s Degree in Mathematics from Northwestern State University in Louisiana.

spacer
James Trammel
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

CPhI India

1-3 December 2010, Mumbai, India

With the Indian market fast becoming a major global economy and with its pharmaceutical market expected to treble over the years to 2015, CPhI India 2009 is a unique chance to link up with the very best in this industry as they gather to discuss the key issues, trends and developments in one location. Generate new alliances, renew existing partnerships and benefit from the dynamic networking opportunities available to actively drive your business forward. Attend CPhI India 2009 – the perfect environment for growth.
More info >>

 
News and Press Releases

ClinTec International

ClinTec International, a global Clinical Research Organisation (“CRO”) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm. With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec. Through this investment, Elephant has entered the attractive clinical research base, where ClinTec operates as a global provider of outsourcing solutions addressing the drug development lifecycle. Managing Partner of Elephant Capital LLP, Gaurav Burman, and Non-Executive Director of Elephant Capital Plc, James Hauslein, have also made personal co-investments in this transaction.
More info >>

 

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement